ImmunoCellular Therapeutics (IMUC) is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential.
IMUC, through its recent acquisition of monoclonal antibody-related technology from Molecular Discoveries, has several novel monoclonal antibodies.
Manish Singh, president and CEO of IMUC, said: “We look forward to working with Antitope and believe that humanizing our antibodies is a key step in preparing these product candidates for human clinical trials, which we are targeting to initiate in 2010.”